Premium
Gene Therapy: Suppression of VEGF by Reversible‐PEGylated Histidylated Polylysine in Cancer Therapy (Adv. Healthcare Mater. 11/2014)
Author(s) -
Cai Xiaojun,
Zhu Haiyan,
Dong Haiqing,
Li Yongyong,
Su Jiansheng,
Shi Donglu
Publication year - 2014
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201470055
Subject(s) - polylysine , pegylation , genetic enhancement , transfection , in vivo , gene delivery , in vitro , cancer research , vegf receptors , neuropilin 1 , gene transfer , cancer therapy , pharmacology , chemistry , cancer , gene , microbiology and biotechnology , medicine , vascular endothelial growth factor , biology , biochemistry , genetics
On page 1818, Y. Y. Li, D. Shi, and co‐workers show that reversible PEGylation and histidylation of polylysine catiomer critically function to facilitate the efficient delivery of siRNA‐VEGF. The unique structural designs significantly affect the gene transfection efficiencies both in vitro and in vivo, and further result in effective inhibition of tumor growth on the murine xenograft models.